Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Imaging of Tc 99m Tilmanocept in RA
NCT02865434Phase 2Completed
- Sponsor
- Navidea Biopharmaceuticals, Inc.
- Start
- Jan 2017
- Primary completion
- Jun 2018
- Modality
- Radiopharmaceutical, Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of technetium tc 99m tilmanocept in rheumatoid arthritis (RA), sponsored by Navidea Biopharmaceuticals, Inc.. Started Jan 2017; status: completed.
02
Drugs
technetium tc 99m tilmanocept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02865434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02865434.